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The impact of some commonly prescribed anti-epilepsy drugs (AEDs) on female health is well documented. Yet many women
continue to experience side effects such as menstrual irregularities, interactions with hormonal contraception/HRT and terato-
genicity [Seizure 8 (1999) 201] through lack of awareness or opportunity to discuss problems with a health professional on a
regular basis.
The ‘Ideal World’ survey aimed to:
(a) assess quality of current treatment information provision to women with epilepsy at different life stages (childbearing age,
pre-conception/pregnancy, menopause);
(b) identify information needs and wants with a view to ensuring that all women with epilepsy are counselled appropriately,
in a timely manner and able to make informed choices about their treatment.
The survey content was developed with a steering group of epilepsy specialists during 2001 (see ‘ACKNOWLEDGEMENTS’)
and mailed to Epilepsy Action (formerly the British Epilepsy Association) UK female membership aged 19+ (approximately
12 000) during the period of January 2002. A sample of 2000 randomly selected responses was analysed by the Planning Shop
International.
The survey shows that women are not receiving important information about their condition and possible adverse effects of
treatment, which could have profound implications for their health and the health of their unborn child. One third (33%) of
women of childbearing age were not considering having children because of their epilepsy.
Women with epilepsy need regular review and should receive appropriate information about the impact of their treatment in
a timely manner.
© 2003 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
The impact on female health of some anti-epilepsy
drugs (AEDs) is well documented1. A recent UK
study revealed that women aged 25–39 years under-
going treatment for epilepsy had significantly lower
fertility rates than those in the general population2.
A higher incidence of menstrual disorders has been
documented among women with epilepsy3. Women
with epilepsy may display a higher prevalence of
Polycystic Ovary Syndrome (PCOS), particularly
those receiving sodium valproate4, 5. Some com-
monly used anti-epilepsy drugs (phenytoin, carba-
mazepine, phenobarbitone, primidone, oxcarbazepine,
and more recently topiramate) are enzyme inducing
and interact with the contraceptive pill, reducing its
effectiveness1 thereby increasing the risk of unplanned
pregnancy.
Among babies born to women with epilepsy, there
is a two- to threefold increase (over the background
1059–1311/$30.00 © 2003 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
Results of the ‘Ideal World’ survey 503
risk of 1–2%) in congenital malformations6. Al-
though other factors such as seizures and a genetic
link between epilepsy and susceptibility to malfor-
mations may contribute to this increase, the greatest
risk is from in utero exposure to AEDs. Major mal-
formations associated with carbamazepine, sodium
valproate and phenytoin1 include congenital heart
disease, cleft lip or palate, limb defects, genitouri-
nary and neural tube defects6. There have been fewer
prospective documented pregnancies on monother-
apy with newer AEDs and so far clear patterns of
teratogenicity have not emerged.
Evidence also suggests that there may be a link be-
tween in utero exposure to AEDs and neurodevelop-
mental delay, particularly with sodium valproate7, 8. It
is therefore essential that a woman is counselled about
these risks well before she conceives. Until the time
that a woman is ready to conceive, it is vital that her
choice of contraception is appropriate and does not
fail her.
Unfortunately current epilepsy services in the UK
are such that many women remain unaware of the
issues or the risks. Important conversations about
contraception and unplanned pregnancy and pre-con-
ception counselling may not take place until it is too
late.
To gain a more accurate picture of the level and qual-
ity of information provided for women about epilepsy
and its treatment, the Ideal World survey set out to
assess the information women want versus that which
they were given (anecdotal experience suggested these
were two different things) and the extent to which
women had been made aware of their treatment op-
tions.
Market research9 revealed that considerable apathy
exists among the majority of women with epilepsy.
Many are disinterested in their condition and don’t
want to be reminded of their epilepsy. It there-
fore seemed necessary to identify which aspects of
epilepsy were considered most pertinent by these
women; quantify the level of demand for informa-
tion; and crucially find out when, how and from
whom women wanted to receive information, with
a view to providing it when the women were most
receptive.
The ‘Ideal World’ survey therefore aimed to:
(a) assess current provision of treatment infor-
mation to women with epilepsy at different
life stages (childbearing age, pre-conception/
pregnancy, menopause);
(b) identify information needs and wants with a
view to ensuring that all women with epilepsy
are counselled appropriately, in a timely manner
and able to make informed choices about their
treatment.
METHOD
The survey content was developed in conjunction with
a steering group of epilepsy specialists during 2001.
Questionnaires were mailed to the female membership
of Epilepsy Action aged 19+ (approximately 12 000)
during the period of January 2002. In addition, the
questionnaire was posted on the Epilepsy Action web-
site and responses collected. In total, 2600 question-
naires plus 90 web responses were completed and
2000 responses were randomly selected and analysed
by the Planning Shop International.
RESULTS
Demographics
Figs 1 and 2 show the numbers of women in each age
group and what medication they are receiving.
What is important to women at different
life stages?
The most important issues for women in the 19–44
age group who were considering having children (n =
498) are (in order of importance):
1. Risk of epilepsy/medication affecting the unborn
child (87%);
2. Effect of pregnancy on seizure control (49%);
3. Risk of a child developing epilepsy (42%).
A full breakdown of results is shown in Fig. 3.
The key issues of importance to women in the
45+ age group are (in order of importance):
1. Epilepsy medication and osteoporosis (63%);
2. Epilepsy medication as you get older (57%);
3. Changes in seizures during the menopause
(44%).
Epilepsy and contraception
Over half (53%) of women in the 19–34 age group
(n = 420) are concerned that some epilepsy med-
ications interact with the contraceptive pill making
it less effective. Forty-five percent of the women (in
the 19–34 age group) who indicated that they were
taking an enzyme-inducing AED had not received
information about oral contraception and epilepsy
medication.
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Fig. 1: Sample demographics (n = 2000).
Epilepsy and pregnancy
One third of women who had already had children
(n = 419) were not given any information about their
pregnancy and epilepsy medication and 13% were
only given information after they became pregnant.
Over half (54%) of the women who had been through
a pregnancy had not been told that their epilepsy med-
ication might affect their unborn child. The majority
of women (75%) who have already had children had
not been referred to a specialist centre or clinic in con-
nection with their pregnancy. Only 7% of women in
Fig. 2: Medication that women are receiving.
the 35–44 age group had been referred for specialist
epilepsy care for their pregnancy. A third (32%) of
women aged 19–44 who are not considering having
children in the future (n = 549), said the decision was
linked to their epilepsy.
Overall, 43% of women who have had children have
been advised about taking folic acid, with a signif-
icantly higher percentage of women in the younger
age group being advised about taking this supple-
ment. As Fig. 4 shows, 63% of women in the younger
age group have been advised about taking folic acid,
compared with only 34% of women in the older age
group. Eleven percent of women who have had chil-
dren had been told about taking Vitamin K therapy
during the last month of pregnancy.
Epilepsy and menopause
A substantial minority of women (39%) over the age of
45 had not been given any information about epilepsy
and its treatment in relation to the menopause/HRT.
Less than a quarter (24%) of women in this age group
are aware that the menopause can upset seizure con-
trol, with 28% aware that some epilepsy treatments
can affect HRT. Twenty-seven percent of women
are aware that some epilepsy treatments can cause
osteoporosis.
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Fig. 3: Topics that women think are most important.
Information needs and wants
The majority of all women (84%) want to be better
informed about treatment decisions while nearly half
(41%) want to take a more proactive role in treatment
Fig. 4: Information given about pregnancy and epilepsy medication. The table shows that 20% were not given any information
at all about pregnancy and epilepsy medication, with the percentage being higher in the 35–44 age group. Nearly a quarter of
this older age group had not received information of this nature, compared with only 13% of the younger age group. This is a
statistically significant difference at 99% confidence.
discussions. Forty-three percent say they want to be
more informed so that they could ask their doctor to
review their medication. The vast majority of women
(87%), who are considering having children, would
like to have more information about epilepsy treatment
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Table 1: Summary of preferred time to receive information.
Effect of epilepsy on Diagnosis Before puberty At puberty Before considering When considering Approaching
(%) (%) (%) pregnancy (%) pregnancy (%) menopause (%)
Periods 35 32 15
Contraception 25 6 30 15 2 1
Pregnancy 17 2 10 42 9 1
Risk of child development
epilepsy
19 1 5 41 15
AEDs + pregnancy/
foetal development
16 1 5 43 13 1
Menopause 19 58
and the possible risk to the unborn child. More than
half (57%) want the latest information on epilepsy
treatment and the risk of birth defects on an ongoing
basis, even if data is incomplete.
There is a high level of interest (72%) amongst
women aged 45+ for receiving information about
epilepsy and its treatment in relation to the menopause/
HRT. As many as 89% of women in this group want to
receive information about epilepsy and osteoporosis.
Ideal time to receive information
In terms of the ideal time to receive information about
the effect of epilepsy treatment at the different life
stages, the survey confirmed a consistent preference
for information before the time that it will be needed.
For example, the majority of women in the survey
want information about the effect of epilepsy on preg-
nancy and on the risk of a child developing epilepsy as
they consider pregnancy. Similarly, women expressed
a desire to have information on the effect of epilepsy
on periods and contraception at puberty. See Table 1
for a summary.
How women wished to receive information
Overall, the majority (59%) of women would like to
receive information in a written format, for example
in a leaflet. Twenty-eight percent would like to receive
information through conversation with a health profes-
sional. There was consistently little interest across all
groups of women in receiving information via video-
tapes (5%), the Internet (4%) or audiocassette (2%),
with only a small percentage of women stating a pref-
erence for information via these means.
DISCUSSION
Women with epilepsy are clearly not receiving im-
portant information regarding treatment, which could
have profound implications for their health and the
health of their unborn child. Women with epilepsy re-
quire a different approach to epilepsy treatment than
men and it is therefore crucial that they receive special
attention and regular treatment reviews, with referral
to a specialist as appropriate, to ensure that the risk of
unplanned pregnancy and birth defects are minimised.
Women clearly want to be better informed, with
many wanting to take a more proactive role in their
treatment and many wanting to work more in part-
nership with their doctors than passively accepting
treatment. Women with epilepsy appear to want
greater control over their treatment and their epilepsy
and provision of appropriate, timely information is
clearly desired by these women to help them achieve
this objective.
Health professionals should encourage women to
discuss aspects of their condition and possible adverse
effects of treatment in a timely fashion—especially
before conception—and where possible, provide the
latest, most up-to-date information.
Even if pregnancy doesn’t seem relevant or a prior-
ity for the patient at that moment in time, it is prudent
to think ahead and discuss the matter with her so that
she is primed for when the time comes. Teens are an
important time to review epilepsy and adjust treatment
if necessary—especially as this avoids inappropriately
timed and disruptive changes later on when the pa-
tient is driving, working or living away from home or
planning to have a family.
Having epilepsy should not be a limiting factor to
having a child. The current situation could be im-
proved by more women-centred clinics offering pre-
conception counselling and treatment review as well
as follow up during pregnancy and beyond. With the
right information and support at the right time, women
with epilepsy can make informed choices and over-
come perceived barriers which often obscure the full
range of options open to them. Very few specialist clin-
ics for women with epilepsy who wish to become preg-
nant exist in the UK10, but are potentially valuable.
CONCLUSION
The survey reveals that women with epilepsy are not
receiving important information regarding treatment
and its possible adverse effects, which could have
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profound implications for their health and the health
of their unborn child.
Previous studies suggest that women with epilepsy
are unlikely to proactively seek a review of their treat-
ment. To improve the current situation, all women
with epilepsy of childbearing age should be offered a
review, initially in general practice, to ensure that ap-
propriate treatment changes can be made in a timely
fashion. Thereafter, regular review and discussion
should be encouraged to discuss treatment and stage
of life issues.
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